EPIRUS Biopharmaceuticals, Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2015. For the quarter, the company reported revenue, net of USD 285,000 compared to USD 4,000 a year ago. Loss from operations was USD 16,085,000 compared to USD 10,156,000 a year ago. Net loss was USD 15,416,000 compared to USD 10,400,000 a year ago. Basic and diluted loss per share was USD 0.63 compared to USD 0.80 a year ago. The revenue in primarily relates to collaboration revenue under the Polpharma agreement and royalties and milestones under the Sun Pharmaceutical agreement.

For the year, the company reported revenue, net of USD 576,000 compared to USD 4,000 a year ago. Loss from operations was USD 52,357,000 compared to USD 39,255,000 a year ago. Net loss was USD 52,210,000 compared to USD 41,844,000 a year ago. Basic and diluted loss per share was USD 2.30 compared to USD 6.81 a year ago. The revenue primarily relates to collaboration revenue under the Polpharma agreement and royalties and milestones under the Sun Pharmaceutical agreement.